CMS
-
Dr. Oz’s Armenian Community Fraud Claims Draw Civil Rights Complaint
California Governor Gavin Newsom has filed a civil rights complaint against Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, following a video where Oz linked Armenian-owned businesses in Los Angeles to large-scale healthcare fraud. The claims…
-
UnitedHealth Shares Plummet as Trump Administration’s Medicare Rate Proposal Shakes Health Sector
UnitedHealth Group’s stock plunged nearly 20% on Tuesday, dragging down the Dow Jones Industrial Average, after the Trump administration proposed a significantly lower-than-expected increase in Medicare Advantage payment rates for 2027.
-
CMS Schools Face Legal Battle Over Free Speech and Weather Disruptions
Charlotte-Mecklenburg Schools (CMS) are under legal and operational scrutiny: a federal lawsuit alleges censorship after a student’s tribute to Charlie Kirk was erased, while widespread weather disruptions test the district’s emergency response.
-
CMS Announces Major Price Cuts for 15 Top Medicare Drugs Under IRA: What It Means for Patients and Pharma
The Centers for Medicare & Medicaid Services (CMS) has unveiled substantial price reductions for 15 high-cost Medicare drugs under the Inflation Reduction Act (IRA), promising significant savings for patients and taxpayers. These changes, effective from January 2027, have sparked questions…
-
Dr. Oz Sparks Outcry With ‘Trump Babies’ Remark During Fertility Drug Announcement
During a press conference at the Oval Office, Dr. Mehmet Oz, now head of CMS, referred to lowering fertility drug prices as a way to make ‘lots of Trump babies,’ triggering widespread backlash and social media mockery.
-
Medicare Drug Price Negotiations to Continue, with Focus on Transparency
The Centers for Medicare & Medicaid Services (CMS) has announced it will proceed with Medicare drug price negotiations under the current administration, emphasizing a commitment to greater transparency in the process. This second round of negotiations will include high-profile, expensive…